24
total announcements
SHILPAMED.NS · 15 min delayed
Shilpa Medicare Limited
Shilpa Medicare Limited has dispatched a letter to shareholders whose email addresses are not registered with the company, registrar, and transfer agent, providing a web-link to the Annual Report for the Financial Year 2025-26 and Notice of the 39th Annual General Meeting.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about a voluntary recall of 27,923 vials of chemotherapy drug in the US due to atypical discoloration. The recall has been classified by the US FDA as a Class II (hospital level) recall. The company does not foresee any material impact on its financial position, operations, or other affairs.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about Dividend Updates. The company has recommended a Dividend of Re. 0.60/- per Equity Share for the financial year ended March 31, 2026. The Board has fixed Friday, 4 September, 2026, as the record date for determining entitlement of members to receive the Final dividend.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about Copy of Newspaper Publication regarding notice of the 39th Annual General Meeting, e-voting and other information to the shareholders.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 11, 2026. The meeting will consider and pass various resolutions, including the appointment of a director, payment of commission to the cost auditors, and ratification of remuneration.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about the transcript of the Q1FY27 Conference call held on August 05, 2026. The company's management discussed their first quarter FY27 results, highlighting their operational leverage, debt reduction, and growth in their API and Formulation divisions.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about the link of recording of their Q1/FY2026-27 Conference Call held on 5th August, 2026. The audio recording is available on their website.
Shilpa Medicare Limited
Shilpa Medicare Limited has announced its 1QFY27 earnings, with revenue and EBITDA growth of 43% and 42% YoY respectively, driven by strong performance across its three key verticals. The company has also announced a credit rating upgrade to AA- and has partnered with Gate2Brain for a novel asset.
Shilpa Medicare Limited
Shilpa Medicare Limited has announced the record date for the payment of final dividend for the financial year 2025-26 as 04-Sep-2026.
Shilpa Medicare Limited
Shilpa Medicare Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 18,904 lakhs and net sales/income from operations at Rs. 16,592 lakhs. The company has also announced the appointment of a new whole-time director, Mr. Sharath Reddy Kalakota, and the payment of remuneration to a non-executive director. Additionally, the company has informed about a proposed strategic long-term equity partnership with Gate2Brain and the schedule for the 39th Annual General Meeting (AGM).
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange regarding the appointment of Dr. Uday N. Harle as Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a wholly owned subsidiary, with effect from August 03, 2026.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about the schedule of its Q1FY27 Earnings Conference Call, to be held on August 05, 2026, at 16:00 hrs.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about Credit Rating revision by India Ratings and Research Pvt Ltd (Fitch Group) for its material subsidiary Shilpa Biologicals Private Limited. The revised ratings are IND A+/Stable/IND A1+ for bank loan facilities.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about the resignation of Dr. Sridevi Khambhampaty as Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a material subsidiary, due to personal commitments.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange about a revision in credit rating issued by India Ratings and Research Pvt. Ltd (Fitch Group) for the company and its subsidiary Shilpa Pharma Lifesciences Ltd. The rating for bank loan facilities has been upgraded to IND AA- from IND A+ with a Stable Outlook.
Shilpa Medicare Limited
Shilpa Medicare Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the details of securities dematerialized or rematerialized during the quarter ended June 30, 2026, as required under Regulation 74(5).
Shilpa Medicare Limited
Shilpa Medicare Limited has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026, along with the appointment of cost auditors and internal auditors, and other corporate updates.
Shilpa Medicare Limited
Shilpa Medicare's wholly owned subsidiary, Shilpa Biologicals, has entered into a co-development and supply agreement with Orion Corporation for intravenous(IV) nivolumab biosimilar. The agreement combines Shilpa's manufacturing capabilities with Orion's commercial and regulatory expertise.
Shilpa Medicare Limited
Shilpa Medicare Limited has published a notice to shareholders regarding the transfer of unclaimed dividends and shares to the Investor Education and Protection Fund (IEPF) as per SEBI Listing Regulations.
Shilpa Medicare Limited
Shilpa Medicare Limited has informed the Exchange regarding the closure of the trading window for its designated persons and their relatives due to the upcoming declaration of unaudited financial results for the quarter ended 30 June 2026.